NEW YORK, December 29, 2025, 10:35 ET
- Live Oak Private Wealth cut its Pfizer stake by 92.5% in the third quarter, a filing showed
- Brookstone Capital more than doubled its Pfizer holding in the same period
- Meyer Handelman trimmed its Pfizer position, ending the quarter with about 1.24 million shares
Live Oak Private Wealth LLC cut its stake in Pfizer (PFE.N) by 92.5% in the third quarter, selling 216,868 shares and ending the period with 17,627 shares, a regulatory filing showed.
The disclosures matter because quarterly holdings reports are one of the few windows investors get into how money managers were positioned in major stocks heading into the final stretch of the year. The filings can signal shifting conviction in Pfizer, a high-profile name in U.S. healthcare.
The reports are known as Form 13F filings, which large investment managers submit to U.S. regulators to list many of their U.S.-traded equity holdings. They show positions as of the quarter-end and do not capture trades made after that date.
Live Oak’s Pfizer holding was valued at about $449,000 at the end of the quarter, the filing’s information table showed.
Brookstone Capital Management lifted its Pfizer stake by 134.1% during the third quarter, acquiring an additional 154,286 shares and ending the period with 269,381 shares, according to its filing.
Brookstone’s Pfizer position was valued at about $6.86 million at quarter-end, the filing summary cited by MarketBeat showed.
Meyer Handelman Co., a larger Pfizer holder among the firms highlighted in recent filings, reduced its position by 3.3% in the third quarter after selling 42,830 shares. It ended the quarter with 1,237,617 shares, worth about $31.53 million, according to the filing.
Other advisers made smaller adjustments. Capital Advisory Group Advisory Services LLC and Citizens National Bank Trust Department each reported modest increases in Pfizer holdings earlier in the year, according to filings cited by MarketBeat.
Hedge funds and other institutional investors own about 68.36% of Pfizer’s shares, MarketBeat said, underscoring how shifts in professional portfolios can influence trading in the stock.
Pfizer shares have traded between $20.92 and $27.69 over the past 12 months, MarketBeat data showed.
Pfizer, based in New York, develops and markets medicines and vaccines.
Because Form 13F disclosures are backward-looking, investors typically treat them as a snapshot rather than a real-time view of portfolio positioning. Still, sharp moves — like Live Oak’s reduction — can draw attention to changing sentiment around widely held large-cap stocks.
